AI-Enabled Drug Discovery and Clinical Trials Market, By Components (Solutions and Services), By Solution (Aggregation & Analysis, Clinical Trials, Drug Design, Drug Characterization, Biomarker Research, and Others), By Application (Oncology, Cardiovascular Diseases, Nervous System Diseases, Respiratory Disorder, Metabolic Diseases Immunologic Diseases, Infectious Diseases, and Others), By End-user (Biopharmaceutical Industry, Contract Research Organizations (CROs), and Academic Institutes and Research Centers), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2029.

Report Code: PMI429620 | Publish Date: March 2024 | No. of Pages: 141

Global AI Enabled Drug Discovery And Clinical Trials Market Overview

 AI-enabled drug discovery and clinical trials market accounted for US$ 0.4 billion in 2020 and is estimated to be 4.34 billion by 2029 and is anticipated to register a CAGR of 30.7%.

Biopharmaceutical companies are the major end users in terms of revenue share for the AI-enabled drug discovery and clinical trials market. The biopharmaceutical company’s market share is projected to growth a comparatively faster rate. Furthermore, the use of the solutions is anticipated to grow in academic & research centers and contract research organizations in order to improve the quality of care and streamline the workflow of the facilities.

Global AI Enabled Drug Discovery And Clinical Trials Market Dynamics

AI is helping companies in manipulating huge patient datasets into digestible, identifying personalized, precision medicine opportunities, tangible information, or potential forecasting responses to new drugs. In addition, examining the electronic medical reports of patients, rising applications of AI to analyze the pool of potential subjects in drug discovery, and genomic data for improved clinical trial matching will support to the growth of AI-enabled drug discovery and clinical trials market. Furthermore, the growth in the application of AI in drug discovery aids from the open-source execution will drive the AI-enabled drug discovery and clinical trial market over the forecast period. AI provides accelerating the treatment options for rare diseases, detects potential rare diseases indications and forecasts new indications for existing medicines. Moreover, increasing adoption of Ai in the pharmacy industry for target discovery, compound screening, compound synthesis, patient recruitment, crystal form prediction, optimization of clinical trial design, and drug redirection will boost the AI-enabled drug discovery and clinical trials in the coming years.

Conversely, lack of regulations and ethical issues are the major challenges faced by the target market.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global AI Enabled Drug Discovery And Clinical Trials Market Segmentation

The AI-enabled drug discovery and clinical trials market is segmented based on components, solution, application, end-user, and region.

On the basis of components, the AI-enabled drug discovery and clinical trials market is segmented into solutions and services. On the basis of solution, the target market is classified into aggregation & analysis, clinical trials, drug design, drug characterization, biomarker research, and others. Based on application, the target market is classified into oncology, cardiovascular diseases, nervous system diseases, respiratory disorder, metabolic diseases immunologic diseases, infectious diseases, and others. On the basis of end-user, the target market is classified into biopharmaceutical industry, contract research organizations (CROs), and academic institutes and research centers.

Regional Insights:

On region the AI-enabled drug discovery and clinical trials market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America estimates for a major share in 2019 and projected to lead the market by 2029 owing to the presence of globally leading pharmaceutical companies and high focus on R&D & substantial investment in the healthcare sector by USA governments.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

 

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2029

Market representation

Revenue in USD Million & CAGR from 2020 – 2029

Market Segmentation

By Components - Solutions and Services

By Solution- Aggregation & Analysis, Clinical Trials, Drug Design, Drug Characterization, Biomarker Research, and Others

By Application - Oncology, Cardiovascular Diseases, Nervous System Diseases, Respiratory Disorder, Metabolic Diseases Immunologic Diseases, Infectious Diseases, and Others

By End-user - Biopharmaceutical Industry, Contract Research Organizations (CROs), and Academic Institutes and Research Centers

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest application trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the AI-enabled drug discovery and clinical trials market report based on components, solution, application, end-user, and region.

AI-Enabled Drug Discovery and Clinical Trials Market, By Components:

  • Solutions
  • Services

AI-Enabled Drug Discovery and Clinical Trials Market, By Solution:

  • Aggregation & Analysis
  • Clinical Trials
  • Drug Design
  • Drug Characterization
  • Biomarker Research
  • Others

 AI-Enabled Drug Discovery and Clinical Trials Market, By Application:

  • Oncology
  • Cardiovascular Diseases
  • Nervous System Diseases
  • Respiratory Disorder
  • Metabolic Diseases Immunologic Diseases
  • Infectious Diseases
  • Others

AI-Enabled Drug Discovery and Clinical Trials Market, By End-user:

  • Biopharmaceutical Industry
  • Contract Research Organizations (CROs)
  • Academic Institutes and Research Centers

AI-Enabled Drug Discovery and Clinical Trials Market, By Region:

  • North America
    • Middle East & Africa
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa
    • Latin America
        • Brazil
        • Mexico
        • Rest of Latin America
    • Asia Pacific
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Europe
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • U.S.
    • Canada

Global AI Enabled Drug Discovery And Clinical Trials Market Key Players

The key players operating the AI-enabled drug discovery and clinical trials market includes Accutar Biotechnology Inc., Ardigen, AiCure, LLC, Atomwise, Inc., Biovista Inc., BenevolentAI, Berg LLC, BioAge Labs, Inc., Berkeley Lights, Inc., and C4X Discovery Holdings Plc. Prominent players are involved in merges and acquisitions in order to expand their market position. For instance, on September 2018, Atomwise Inc., a leader in Artificial Intelligence (AI) for drug discovery and design, has entered into an evaluation agreement with Pfizer Inc. Pfizer will evaluate Atomwise’s platform to identify potential drug candidates for up to three target proteins selected by Pfizer.

Global AI Enabled Drug Discovery And Clinical Trials Market Company Profile

  • Accutar Biotechnology, Inc.
    • Company Overview
    • Product Components Portfolio
    • Key Highlights
    • Financial PerRaw Materialance
    • Business Strategies
  • Ardigen
  • AiCure, LLC
  • Atomwise, Inc.
  • Biovista Inc.
  • BenevolentAI
  • Berg LLC
  • BioAge Labs, Inc.
  • Berkeley Lights, Inc.
  • C4X Discovery Holdings Plc

“*” marked represents similar segmentation in other categories in the respective section

Global AI Enabled Drug Discovery And Clinical Trials Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Preview
    • Executive Summary
    • Key Findings—Global Outlook for AI-Enabled Drug Discovery and Clinical Trials Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Components
      • Market Snippet, By Solution
      • Market Snippet, By Application
      • Market Snippet, By End-user
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Market Segmentation, By Components, 2020 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2029
      • Y-o-Y Growth Analysis (%), 2020 – 2029
      • Segment Trends
    • Solutions
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Services
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
      •  
  6. Market Segmentation By Solution, 2020 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2029
      • Y-o-Y Growth Analysis (%), 2020 – 2029
      • Segment Trends
    • Aggregation & Analysis
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Clinical Trials
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Drug Design
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Drug Characterization
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Biomarker Research
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
  7. Market Segmentation, By Application, 2020 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2029
      • Y-o-Y Growth Analysis (%), 2020 – 2029
      • Segment Trends
    • Oncology
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Cardiovascular Diseases
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Nervous System Diseases
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Respiratory Disorder
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Metabolic Diseases Immunologic Diseases
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Infectious Diseases
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
  8. Market Segmentation, By End-user, 2020 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2029
      • Y-o-Y Growth Analysis (%), 2020 – 2029
      • Segment Trends
    • Biopharmaceutical Industry
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Contract Research Organizations (CROs)
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Academic Institutes and Research Centers
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
  9. Global Market, By Region, 2020 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2029
      • Y-o-Y Growth Analysis (%), 2020 – 2029
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Components, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Solution, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By End-user, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2029
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Components, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Solution, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By End-user, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2029
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Components, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Solution, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By End-user, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2029
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Components, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Solution, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By End-user, 2020 – 2029
      • Market Size  and Forecast (US$ Mn), By Country, 2020 – 2029
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Components, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Solution, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By End-user, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2029
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  10. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  11. Company Profiles
      • Accutar Biotechnology Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Business Strategies
      • Ardigen
      • AiCure, LLC
      • Atomwise, Inc.
      • Biovista Inc.
      • BenevolentAI
      • Berg LLC
      • BioAge Labs, Inc.
      • Berkeley Lights, Inc.
      • C4X Discovery Holdings Plc
  12. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The global AI-enabled drug discovery and clinical trials market is segmented based on components, solution, application, end-user, and region.

Increasing adoption of Ai in the pharmacy industry for target discovery, compound screening, compound synthesis, patient recruitment, crystal form prediction, optimization of clinical trial design, and drug redirection will boost the AI-enabled drug discovery and clinical trials in the coming years.

North America estimates for a major share in 2019 and projected to lead the market by 2029 owing to the presence of globally leading pharmaceutical companies and high focus on R&D & substantial investment in the healthcare sector by USA governments.

Prominent players are involved in merges and acquisitions in order to expand their market position. For instance, on September 2018, Atomwise Inc., a leader in Artificial Intelligence (AI) for drug discovery and design, has entered into an evaluation agreement with Pfizer Inc. Pfizer will evaluate Atomwise’s platform to identify potential drug candidates for up to three target proteins selected by Pfizer.